Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ambrx Biopharma, Inc. - Common Stock (NY:AMAM)

N/A UNCHANGED
Last Price Updated: 7:00 PM EDT, Mar 16, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ambrx Biopharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
3 Dividend Stocks That Are Too Good to Ignore: Q1 Edition
Here are the three dividend stocks that will never disappoint you. Buy them while they trade at a discount. 
Via InvestorPlace
3 Stocks to Buy That Are Up 200% or More in 2024
Each of these stocks up 200% in 2024 offer unique upside opportunities for investors, including equity arbitrage plays. 
Via InvestorPlace
The 3 Biotech Stocks That Could Make Your February Unforgettable
After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks. 
Via InvestorPlace
Looking Into Ambrx Biopharma's Recent Short Interest
 
Via Benzinga
Better Growth Stock: UnitedHealth Group vs. Johnson & Johnson
These companies have been focusing on growing their operations, but which stock is likely to provide investors with better returns? 
Via The Motley Fool
Assessing Ambrx Biopharma: Insights From 7 Financial Analysts
 
Via Benzinga
Health Care Company Johnson & Johnson Announces Merger With Ambrx Biopharma
 
Via Benzinga
Analyst Ratings for Ambrx Biopharma
 
Via Benzinga
Analyst Ratings for Ambrx Biopharma
 
Via Benzinga
Johnson & Johnson Secures Complete FDA Approval For Bladder Cancer Drug Balversa, After Almost Five Years Of Accelerated Approval
FDA-approved Balversa for urothelial carcinoma treatment. The first oral FGFR kinase inhibitor offers clinical benefits, extended overall survival, and a breakthrough for FGFR alterations in metastatic... 
Via Benzinga
Johnson & Johnson's Q4 Earnings: Spotlight On Dividend Security Following Kenvue Split, Legal Costs, Acquisitions
Johnson & Johnson (JNJ) to report Q4 earnings on Jan. 23, with expectations of $2.28 EPS and $20.99B revenue. Strong, diverse company with reliable dividend, but impacted by talc lawsuit settlement and... 
Via Benzinga
Topics Lawsuit
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will... 
Via Talk Markets
Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review
The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut. 
Via Investor's Business Daily
Topics ETFs
Dow Surges Over 100 Points; Commercial Metals Posts Upbeat Q1 Results
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.35% to 37,596.43 while the NASDAQ rose 1.89% to 14,799.21. The... 
Via Benzinga
Topics Stocks
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Crude Oil Falls Sharply; Ambrx Biopharma Shares Spike Higher
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining more than 1% on Monday. The Dow traded down 0.19% to 37,396.28 while the NASDAQ rose 1.20% to 14,698.88. The S&P 500... 
Via Benzinga
Topics Stocks
Why Is Ambrx Biopharma (AMAM) Stock Up 100% Today?
With Johnson & Johnson buying out Ambrx Biopharma, the win-win deal boosted AMAM stock while better positioning J&J’s oncology unit. 
Via InvestorPlace
Today Is Cancer-Focused Deals Day: Johnson & Johnson Scoops Up Ambrx Biopharma As Merck Boosts Cancer Portfolio With Harpoon Deal
Monday, Johnson & Johnson (NYSE: JNJ) has agreed to acquire Ambrx Biopharma Inc (NASDAQ: AMAM) in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billi 
Via Benzinga
US Stocks Mixed; Nasdaq Jumps Over 100 Points
U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around 100 points on Monday. Following the market opening Monday, the Dow traded down 0.45% to 37,296.85 while the NASDAQ rose... 
Via Benzinga
Topics Stocks
J&J, Merck, Boston Scientific Debut Trio Of Splashy Takeovers Topping $3 Billion In Value
The year's biggest medical conference kicked off with a melee of buyout news. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Biggest Short Squeeze Stocks Of The Week: Biotech Stocks Dominate, A Bitcoin-Related Stock Moves Up Leaderboard
Potential short squeeze plays gained steam in 2021, continued throughout 2022 and remained a focus of traders looking for the next big move. High short interest and steep borrowing costs are among the... 
Via Benzinga
Biggest Short Squeeze Stocks Of The Week: Two Biotech Stocks Move Up To Top The List
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of traders looking for the next huge move. High short interest and steep borrowing costs are among the... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Why EngageSmart Shares Are Trading Higher By Around 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers INVO Bioscience, Inc. (NASDAQ: INVO) jumped 375% to $2.57 as the company agreed to acquire NAYA Biosciences in an all-stock transaction. 
Via Benzinga
FMC, Li-Cycle Holdings, Okta And Other Big Stocks Moving Lower On Monday
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 10 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why ServisFirst Bancshares Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc. 
Via Benzinga
Why Vistagen Therapeutics Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares surged 79.5% to $5.08 in pre-market trading after falling around 7% on Monday. SciSparc recently regained compliance with the Nasdaq Minimum Bid Price... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.